A Randomized, Placebo-Controlled, Blinded Clinical Trial Evaluating PCSO-524 as an Adjunctive Therapy for Noninfectious Pododermatitis in Rabbits

Sep 29, 2026

Uploaded by Terk

Research evaluates the efficacy and safety of PCSO-524, a natural supplement containing omega-3 fatty acids, as adjunctive therapy for noninfectious pododermatitis (Grades 1-2) in rabbits. In a randomized, placebo-controlled, blinded trial, 23 rabbits received PCSO-524 or placebo alongside standard treatments for 56 days. PCSO-524 reduced mean lesion size in hind limbs versus baseline with statistical significance, unlike placebo. Both groups showed blood cell changes and an elevated heterophil-to-lymphocyte ratio within ranges, and no adverse events were linked to PCSO-524.

LanguageEnglish

CategoryHealthcare

FormatPDF

Pages9

Reading Time23 min

AccessFree to download

Introduction

Pododermatitis and risk factors in rabbits

Treatment challenges and rationale for PCSO-524

Study hypothesis and aims

Materials and Methods

Animals

Wiley Veterinary Medicine International Volume 2025, Article ID 4177859, 9 pages [https://doi.org/10.1155/vmi/4177859](https://doi.org/10.1155/vmi/4177859) Research Article A Randomized, Placebo-Controlled, Blinded Clinical Trial Evaluating PCSO-524 as an Adjunctive Therapy for Noninfectious Pododermatitis in Rabbits Walasinee Sakcamduang , 1 Nijanan Siriarchawattana ,2 Phattanan Korjaranjit ,2 Vitthanan Natepoo,2 Nawarat Suriyakhun,3 Chaowaphan Yinharnmingmongkol ,4 and Mookmanee Taechikantaphat 1 1 Department of Clinical Sciences and Public Health, Faculty of Veterinary Science, Mahidol University, Nakhon Pathom 73170, Tailand 2 Faculty of Veterinary Science, Mahidol University, Nakhon Pathom 73170, Tailand 3 Prasu Arthorn Veterinary Teaching Hospital, Faculty of Veterinary Science, Mahidol University, Nakhon Pathom 73170, Tailand 4 Animal Space Pet Hospital, Tawi Watthana, Bangkok 10170, Tailand Correspondence should be addressed to Mookmanee Taechikantaphat; [mookmanee.tan@mahidol.ac.th](mookmanee.tan@mahidol.ac.th) Received 18 March 2025; Revised 23 October 2025; Accepted 20 November 2025 Academic Editor: Hassan Al-Karagoly Copyright © 2025 Walasinee Sakcamduang et al. Veterinary Medicine International published by John Wiley & Sons Ltd. Tis isan open access article under the terms of the Creative Commons Attribution License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited. Tis study evaluated the efcacy and safety of PCSO-524, a natural supplement containing omega-3 fatty acids, as an adjunctive therapy for noninfectious pododermatitis (Grades 1-2) in rabbits. In a randomized, placebo-controlled, blinded trial, 23 rabbits with noninfectious pododermatitis received either PCSO-524 or a placebo along with standard treatments for 56 days. PCSO-524 supplementation led to a statistically signifcant reduction in the mean lesion size of both hind limbs within the PCSO group compared to baseline (Day 0: 98 .55 ± 52. 75 mm2, Day 56: 53 .18 ± 21. 54 mm2; p 􀂈 0.002), while the placebo group did not show signifcant changes (Day 0: 93 .98 ± 43. 88 mm2, Day 56: 75 .61 ± 115. 68 mm2; p 􀂈 0.58) . Both groups exhibited alterations in white blood cell populations (increased monocytes, decreased eosinophils) within normal ranges, and a consistently elevated heterophil-to-lymphocyte ratio (HLR; > 1:1) . No adverse events were associated with PCSO-524 . Tis study provides initial evidence for the safety and potential efcacy of a natural supplement containing omega-3 fatty acids as an adjunctive therapy for noninfectious pododermatitis in rabbits. Keywords: infammation; omega-3 fatty acids; PCSO-524; pododermatitis; rabbit 1. Introduction Pododermatitis, a common infammatory skin condition in rabbits, birds, and rodents, signifcantly impacts animal health and welfare [1] . Rabbits are particularly susceptible due to their thin plantar skin and lack of footpads, predisposing them to pressure sores and subsequent complications [2, 3] . Several factors contribute to pododermatitis in rabbits. Predisposing factors include breed (e.g., shortcoated breeds like Rex having less protective fur) and body size (e.g., large breeds like Flemish Giant) . Anatomical abnormalities leading to abnormal weight distribution also increase risk. Environmental factors include unsuitable fooring (e.g., wire cages), lack of mobility due to restricted space, and unhygienic housing contaminated with urine or feces [2, 4–6] . Te pathogenesis ofpododermatitis typically begins with pressure-induced ischemia and necrosis of the plantar skin. Reduced blood perfusion leads to free radical damage, thrombosis, and progressive ulceration. Untreated lesions or 2 Veterinary Medicine International improper management can result in secondary bacterial infections and severe infammation [1, 5] . Te severity of pododermatitis is often classifed using a grading system, with early si

FAQs

What was PCSO-524 tested for in this study?

PCSO-524 was evaluated as an adjunctive therapy for noninfectious pododermatitis (Grades 1-2) in rabbits.

How was the trial designed?

The study used a randomized, placebo-controlled, blinded design, comparing PCSO-524 with a placebo alongside standard treatments over 56 days.

Did PCSO-524 affect lesion size and were adverse events observed?

PCSO-524 significantly reduced mean lesion size in both hind limbs versus baseline, while placebo did not show significant changes. No adverse events were associated with PCSO-524.

Sep 29, 2026

Uploaded by Terk